Therapeutic response to a novel enzyme-targeting radiosensitization treatment (KORTUC II) for residual lesions in patients with stage IV primary breast cancer, following induction chemotherapy with epirubicin and cyclophosphamide or taxane.
Therapeutic response to a novel enzyme-targeting radiosensitization treatment (KORTUC II) for residual lesions in patients with stage IV primary breast cancer, following induction chemotherapy with epirubicin and cyclophosphamide or taxane.
复制标题
表柔比星和环磷酰胺或紫杉烷诱导化疗后，IV 期原发性乳腺癌患者残余病灶对新型酶靶向放射增敏治疗 (KORTUC II) 的治疗反应。
DOI：
10.3892/ol.2016.5456
复制
发表时间：
2017-01
期刊：
影响因子：
2.9
通讯作者：
Miyamura M
中科院分区：
文献类型：
--
作者：
Aoyama N;Ogawa Y;Yasuoka M;Iwasa H;Miyatake K;Yoshimatsu R;Yamanishi T;Hamada N;Tamura T;Kobayashi K;Murata Y;Yamagami T;Miyamura M
基于直线加速器的放射治疗对大多数晚期肿瘤的影响可以忽略不计。因此，开发了一种利用过氧化氢和透明质酸钠的新型放射增敏治疗方法高知双氧放射治疗不可切除癌 II (KORTUC II)。 KORTUC II 对于治疗化疗耐药的锁骨上淋巴结转移和复发性乳腺癌的有效性先前已得到证实。本研究评估了 KORTUC II 在 IV 期原发性乳腺癌患者中的安全性和有效性。七名患者（年龄范围，36-65 岁）入组。所有患者在 KORTUC II 治疗前均接受诱导化疗，并在 KORTUC II 治疗前和治疗后 2-7 个月接受正电子发射断层扫描 - 计算机断层扫描 (PET-CT) 检查，并在可能的情况下每六个月接受一次检查。放疗方案（X射线照射）为2.75戈瑞（Gy）/分次，每周5次，共16-18次，总辐射剂量为44-49.5Gy。从第六次放射治疗分次开始给予 KORTUC II 剂（3-6 ml：直径 <3 cm 的病灶 3 ml，≥3 cm 的病灶 6 ml），并在超声引导下每周进行两次。在KORTUC II治疗之前和之后通过PET-CT检查评估治疗效果。在七名患者的七个病变中，五个表现出完全缓解，两个表现出部分缓解，没有一个表现出疾病稳定或疾病进展。治疗后 1 年总生存率为 100%，2 年总生存率为 86%。截至 2014 年 12 月的平均随访时间为 51 个月。 PET-CT研究结果表明，KORTUC II治疗效果显着，治疗效果满意，不良反应可接受。
Linac-based radiotherapy has a negligible effect on the majority of advanced neoplasms. Therefore, a novel radiosensitization treatment Kochi Oxydol Radiation Therapy for Unresectable Carcinomas II (KORTUC II), which utilizes hydrogen peroxide and sodium hyaluronate was developed. The effectiveness of KORTUC II for the treatment of chemotherapy-resistant supraclavicular lymph node metastases and recurrent breast cancers has previously been demonstrated. The present study evaluated the safety and efficacy of KORTUC II in patients with stage IV primary breast cancer. Seven patients (age range, 36–65 years) were enrolled. All patients received induction chemotherapy prior to KORTUC II treatment and underwent positron emission tomography-computed tomography (PET-CT) examinations prior to and 2–7 months following KORTUC II treatment, and every six months thereafter where possible. The radiotherapy regimen (x-ray irradiation) was 2.75 gray (Gy)/fraction, 5 fractions/week for 16–18 fractions with a total radiation dose of 44–49.5 Gy. Administration of the KORTUC II agent (3–6 ml: 3 ml for a lesion <3 cm in diameter and 6 ml for a lesion ≥3 cm) was initiated from the sixth radiotherapy fraction, and was conducted twice a week under ultrasonographic guidance. The therapeutic effects were evaluated by PET-CT examinations prior to and following KORTUC II treatment. Of the seven lesions from the seven patients, five exhibited complete responses, two exhibited partial responses and none exhibited stable disease or progressive disease. The overall survival rate was determined to be 100% at 1 and 86% at 2 years post-treatment. The mean duration of follow-up by December 2014 was 51 months. The results of the PET-CT studies indicated that KORTUC II treatment demonstrated marked therapeutic effects with satisfactory treatment outcomes and acceptable adverse effects.
影响因子：
5.2
作者：
Tsuzuki A;Ogawa Y;Kubota K;Tokuhiro S;Akima R;Yaogawa S;Itoh K;Yamada Y;Sasaki T;Onogawa M;Yamanishi T;Kariya S;Nogami M;Nishioka A;Miyamura M
通讯作者：
Miyamura M